Key Takeaways
- Apnimed's AD109, addressing the neuromuscular dysfunction component of obstructive sleep apnea (OSA), offers a complementary solution to GLP-1 therapies like Eli Lilly's Zepbound, potentially benefiting both obese and non-obese OSA patients.
Lawrence Miller is not afraid of giants. The CEO of sleep apnea-focused Apnimed believes that even though Eli Lilly’s Zepbound...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on In Vivo for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?